AnnJi Pharmaceutical News

Dedicated to New Drug Development in Dermatology & Neurology

AnnJi Invited to Meet with President Tsai as a Recipient of 2023 Bio Taiwan Awards


President Tsai Ing-wen hosted the recipients of the “2023 Outstanding Company” Award at the Presidential Palace on December 8, 2023. Dr. Nick Li attended the reception on behalf of AnnJi Pharmaceutical Co. (AnnJi), the winner of the “Emerging Company of the Year “.

AnnJi is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy’s disease, or SBMA (Spinal and bulbar muscular atrophy).

Scroll to Top